Quinupramine, キヌプラミン

It's only fair to share...Flattr the authorPin on PinterestEmail this to someone
Buffer this pageDigg thisShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInShare on YummlyShare on VKShare on RedditShare on StumbleUponPrint this pageShare on Tumblr

 

Quinupramine

Quinupramine

キヌプラミン

  • 5-(1-azabicyclo[2.2.2]oct-3-yl)-10,11-dihydro-5H-dibenz[b,f]azepine
  • Formula:C21H24N2
  • MW:304.44 g/mol
  • CAS:31721-17-2
Quinupramine
CAS Registry Number: 31721-17-2
CAS Name: 5-(1-Azabicyclo[2.2.2]oct-3-yl)-10,11-dihydro-5H-dibenz[b,f]azepine
Additional Names: 10,11-dihydro-5-(3-quinuclidinyl)-5H-dibenz[b,f]azepine
Manufacturers’ Codes: LM-208
Trademarks: Kinupril (Bellon); Kevopril (Rhone-Poulenc)
Molecular Formula: C21H24N2
Molecular Weight: 304.43
Percent Composition: C 82.85%, H 7.95%, N 9.20%
Literature References: Analog of imipramine, q.v. Prepn: C. Gueremy, P. C. Wirth, DE 2030492 (1971 to Sogeras), C.A. 74,141581e (1971). Animal studies: W. Van Dorsser, A. Dresse, Arch. Int. Pharmacodyn. Ther. 208, 373 (1974); eidem, ibid. 220, 164 (1976). Clinical study: R. Volmat et al., Clin. Neurol. Psychiat. 239, 445 (1978).
Properties: Crystals, mp 150°.
Melting point: mp 150°
Therap-Cat: Antidepressant.
Keywords: Antidepressant; Tricyclics.

Quinupramine (brand names KevoprilKinuprilAdeprimQuinuprine) is a tricyclic antidepressant (TCA) used in Europe for the treatment of depression.[1][2]

Pharmacologically, quinupramine acts in vitro as a strong muscarinic acetylcholine receptor antagonist (anticholinergic) and H1 receptorantagonist (antihistamine), moderate 5-HT2 receptor antagonist, and weak serotonin and norepinephrine reuptake inhibitor.[3] It has negligible affinity for the α1-adrenergicα2-adrenergicβ-adrenergic, or D2 receptor.[3]

Clinically, quinupramine is reported to be stimulating similarly to imipraminedesipramine, and demexiptiline.[4] It can be inferred that its in vivo metabolites may have stronger effects on the reuptake of norepinephrine and/or serotonin than quinupramine itself

SYN

 

References

  1. ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 908. ISBN 3-88763-075-0.
  2. ^ José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. p. 248. ISBN 978-3-527-31058-6.
  3. Jump up to:a b Sakamoto H, Yokoyama N, Kohno S, Ohata K (December 1984). “Receptor binding profile of quinupramine, a new tricyclic antidepressant”. Japanese Journal of Pharmacology36 (4): 455–60. doi:10.1254/jjp.36.455PMID 6098759.
  4. ^ Kent, Angela; M. Billiard (2003). Sleep: physiology, investigations, and medicine. New York: Kluwer Academic/Plenum. p. 233. ISBN 0-306-47406-9.
    • DOS 2 030 492 (Sogeras; appl. 20.6.1970; GB-prior. 20.6.1969).
    • GB 1 252 320 (Sogeras; valid from 29.5.1970; prior. 20.6.1969).

 

Quinupramine
Quinupramine.svg
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life 33 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ECHA InfoCard 100.046.149 Edit this at Wikidata
Chemical and physical data
Formula C21H24N2
Molar mass 304.43 g/mol g·mol−1

//////////////Quinupramine, キヌプラミン

It's only fair to share...Flattr the authorPin on PinterestEmail this to someone
Buffer this pageDigg thisShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInShare on YummlyShare on VKShare on RedditShare on StumbleUponPrint this pageShare on Tumblr

Leave a Reply

Your email address will not be published. Required fields are marked *